【摘要】：目的了解華法林在我院腎病患者中的應(yīng)用情況。方法收集北京大學(xué)第一醫(yī)院2014-07-01—2014-12-31在腎內(nèi)科病房住院并服用華法林的患者的臨床資料,對患者服用華法林的適應(yīng)證、用藥劑量、國際標(biāo)準(zhǔn)化比值(INR)目標(biāo)范圍和住院期間INR水平,以及相關(guān)藥物不良反應(yīng)等進(jìn)行統(tǒng)計分析。結(jié)果共納入150名服用華法林的患者�；颊邞�(yīng)用華法林的適應(yīng)證共有6項,主要用于腎病綜合征患者血漿白蛋白明顯降低時的預(yù)防性抗凝治療(130例,占86.67%)。127例患者為首次使用華法林,其初始劑量有3 mg(65例)、1.5 mg(52例)或2.25 mg(10例),維持劑量為(2.46±1.26)mg�；颊叩腎NR目標(biāo)范圍存在較大差異,其中75例(50.00%)患者出院時INR1.5,103例(68.67%)出院時INR2.0。發(fā)生可能與華法林相關(guān)的出血事件6例,發(fā)生率為4.00%。結(jié)論腎病患者服用華法林的劑量較低,INR值較低,是否需要進(jìn)行藥學(xué)干預(yù),還需要進(jìn)一步的循證學(xué)證據(jù)和臨床試驗結(jié)果支持。
[Abstract]:Objective to investigate the application of warfarin in patients with kidney disease in our hospital. Methods the clinical data of patients hospitalized in the Department of Nephrology and taking warfarin in the first Hospital of Peking University were collected. The indications, dosage, target range of international standardized ratio (INR) and INR level during hospitalization, as well as related adverse drug reactions, were statistically analyzed. Results A total of 150 patients taking warfarin were included. There were 6 indications of warfarin, which were mainly used in prophylactic anticoagulant therapy (130 cases, 86.67%) when plasma albumin was significantly decreased in patients with nephrotic syndrome. 127 patients were treated with warfarin for the first time, the initial dose was 3 mg (65 cases), 1.5 mg (52 cases) or 2.25 mg (10 cases), and the maintenance dose was (2.46 鹵1.26) mg.. There were significant differences in the target range of INR in 75 patients (50.00%). INR 1.5103 cases (68.67%) were discharged from hospital with INR 1.5103 cases (68.67%). Bleeding events related to warfarin occurred in 6 cases (4.00%). Conclusion the dose of warfarin is low and the INR value is low in patients with kidney disease. Further evidence-based evidence and clinical trial results are needed to support the need for pharmaceutical intervention.
【作者單位】： 北京大學(xué)第一醫(yī)院藥劑科;北京大學(xué)藥學(xué)院藥事管理與臨床藥學(xué)系;
【基金】：國家自然科學(xué)基金資助項目(81273592,81202592,81573504)
【分類號】：R692

【參考文獻(xiàn)】

相關(guān)期刊論文 前2條

1 孫藝紅;;華法林抗凝治療的中國專家共識[J];中華內(nèi)科雜志;2013年01期

2 心房顫動抗栓研究協(xié)作組;胡大一;孫藝紅;張鶴萍;姜立清;;華法林對非瓣膜病心房顫動抗栓的安全性和有效性研究[J];中華內(nèi)科雜志;2006年10期

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 黎賽;鄭萍;;1例口服華法林患者PT-INR異常升高的病例分析和藥學(xué)監(jiān)護(hù)[J];中南藥學(xué);2016年12期

2 顧欣;孫安修;張新江;唐鐵鈺;胡月;;服用華法林患者用藥合理性、安全性和依從性評價[J];中國藥物警戒;2016年12期

3 王兵;鄺土光;龔娟妮;李積鳳;楊媛華;;老年急性肺栓塞患者華法林抗凝治療最佳起始劑量探究[J];中華老年心腦血管病雜志;2016年12期

4 孫雪穎;甄文華;;一例心室附壁血栓合并消化道出血患者的抗栓藥物分析[J];今日藥學(xué);2016年11期

5 張姬;陶海燕;;老年下肢深靜脈血栓患者口服華法林的延續(xù)護(hù)理[J];解放軍護(hù)理雜志;2016年22期

6 陳文文;黨和勤;耿濤;王彥輝;劉燕琳;李振山;張秀珍;;影響房顫患者華法林抗凝控制質(zhì)量的因素分析[J];中國醫(yī)院藥學(xué)雜志;2016年24期

7 趙淑娟;趙紅衛(wèi);蔡海霞;陳博雅;曹晶晶;秦玉花;;心內(nèi)科臨床藥師在藥物治療實踐中的典型案例分析[J];中國臨床藥理學(xué)雜志;2016年21期

8 邊原;蔡璐璐;龍恩武;周楊林;杜姍;申青;陳s，

本文編號：2509907